The JN.1 variant of COVID-19 now accounts for approximately 62% of cases in the United States, according to the Centers for Disease Control and Prevention (CDC). This offspring of the BA.2.86 variant has become the most widely circulated variant both in the US and globally. The CDC also revealed that JN.1 is the dominant variant in Europe and is rapidly spreading in Asia.
This latest data from the CDC shows a significant increase in the prevalence of the JN.1 variant compared to previous estimates. The projected range of cases caused by the variant has risen from 39% to 50%, as of December 23, to the current range of 55% to 68%.
However, the CDC emphasized that there is currently no evidence suggesting that JN.1 causes more severe disease. Furthermore, the agency remains optimistic that the existing vaccines will provide increased protection against this variant.
In addition to the concerning rise of the JN.1 variant, COVID-19 hospitalizations in the US have also increased by 20.4% during the week ending on December 30, according to the CDC’s latest update. This surge in hospitalizations underscores the urgent need for continued vigilance in preventing the spread of the virus.
The World Health Organization (WHO) classified the JN.1 variant as a variant of interest in December. At that time, the WHO stated that there was low risk to public health based on the available evidence regarding this strain.
As the JN.1 variant continues to spread across the globe, it is crucial for individuals to adhere to public health guidelines, including mask-wearing, social distancing, and vaccination. These measures remain the cornerstone for mitigating the impact of the virus and protecting ourselves and those around us.
In summary, the CDC’s latest announcement reveals that the JN.1 variant is now the dominant strain in the United States, accounting for approximately 62% of COVID-19 cases. While the variant’s prevalence has increased, there is currently no evidence suggesting it causes more severe disease. The CDC remains confident that current vaccines will provide protection against the JN.1 variant. In light of rising hospitalizations, it is imperative for the public to continue following recommended guidelines to curb the spread of the virus and protect public health.
